| Assessment Status |
Assessment process complete |
| HTA ID |
- |
| Drug |
Paritaprevir boosted with ritonavir and ombitasvir with or without dasabuvir |
| Brand |
(Vierkirax®)/(Exviera®) |
| Indication |
Exviera® is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (CHC) in adults. Exviera® must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera® combination therapy are viekirax® or viekirax® and ribavirin. Viekirax® is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (CHC) in adults viekirax® must not be administered as monotherapy. Depending on the patient population, the recommended co-administered medicinal products for viekirax® are exviera® or exviera® and ribavirin or ribavirin. |
| Rapid review commissioned |
21/12/2014 |
| Rapid review completed |
13/01/2015 |
| Rapid review outcome |
Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE |
15/01/2015 |
| NCPE assessment completed |
10/02/2016 |
| NCPE assessment outcome |
Reimbursement recommended in certain sub-populations of patients with genotype 1 & 4 |
